Ex vivo T lymphocyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution

被引:23
作者
Carlens, S
Gilljam, M
Remberger, M
Aschan, J
Christensson, B
Dilber, MS
机构
[1] Huddinge Univ Hosp, Dept Clin Immunol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Dept Hematol, S-14186 Huddinge, Sweden
[3] Huddinge Univ Hosp, Dept Pathol, S-14186 Huddinge, Sweden
[4] Huddinge Univ Hosp, Ctr Allogene Stem Cell Transplantat, S-14186 Huddinge, Sweden
关键词
T lymphocyte; serum-free medium; retroviral transduction;
D O I
10.1016/S0301-472X(00)00526-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. In the setting of allogeneic stem cell transplantation, suicide gene-manipulated donor T cells that can be selectively inactivated in vivo would potentially allow optimal control of the GVL (graft-vs-leukemia)/GVHD (graft-vs-host disease) balance. Retroviral T-cell transduction requires ex vivo cell expansion, which is often achieved by IL-2 and anti-CD3 stimulation. Traditionally, culture media for cell expansion are supplemented with fetal bovine serum (FBS) or human serum. While these sera promote cell growth and viability, they contain uncharacterized elements that may yield inconsistent results from batch to batch. Cell expansion in serum-free media would therefore be preferable. Materials and Methods. We compared T-cell expansion rates in three commercially available serum-free culture media (X-VIVO 15, AIM-V, and Cellgro SCGM), with or without the addition of human serum (HS, 5%). We also aimed to evaluate how the in vitro expansion affected the composition of the various T cell subsets. Puffy-coats from four healthy donors were expanded for 21 days. The media were compared to standard RPMI 1640 medium, supplemented with HS (5%) or FBS (10%). For retroviral transductions, the LN vector carrying the neomycin- resistance gene was used in four additional donors. Results. In our hands, X-VIVO 15 gave the highest rate of serum-free expansion (a median of 79-fold expansion, range 20-117). For serum-free expansion, activation, with OKT3 for 21 days gave slightly higher expansion rates than a 5-day course (however, without statistical significance). When serum was added, this discrepancy was not seen. Cytokine analysis (IFN-gamma, IL-10, and IL-4) showed a distinct type1 cytokine pattern with elevated IFN-gamma levels during the whole period of culture. Flow cytometric analyses showed substantial inter-media, but also some inter-donor, variability in T-cell subset compositions. Transduction of cells,vith the LN vector and G418 selection resulted in a 14-fold increase (range 3-18) for serum-free X-VIVO 15 based cultures. Cell phenotypes remained unchanged by the transduction procedure as compared to nontransduced cells. Conclusion. Among the tested serum-free media, X-VIVO 15 has shown to best support the in vitro expansion of T cells, resulting in equal percentages of CD4(+) and CD8(+) cells. These cells can easily be transduced and selected. There seem to be no significant benefits, regarding absolute cell numbers or T-cell subset compositions, with OKT3-stimulation for more than five days. The addition of low levels of HS increases the consistencies in the cell expansion rates for all media. (C) 2000 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:1137 / 1146
页数:10
相关论文
共 32 条
[1]  
ASCHAN J, 1991, BONE MARROW TRANSPL, V7, P113
[2]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[3]  
Carlens S, 1998, CLIN TRANSPLANT, V12, P84
[4]  
CHAMPLIN R, 1990, BLOOD, V76, P418
[5]   In vivo alloreactive potential of ex vivo expanded primary T lymphocytes [J].
Contassot, E ;
Murphy, W ;
Angonin, R ;
Pavy, JJ ;
Bittencourt, MC ;
Robinet, R ;
Reynolds, CW ;
Cahn, JY ;
Herve, P ;
Tiberghien, P .
TRANSPLANTATION, 1998, 65 (10) :1365-1370
[6]   Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive T lymphocytes [J].
Contassot, E ;
Ferrand, C ;
Certoux, JM ;
Reynolds, CW ;
Jacob, W ;
Chiang, YW ;
Cahn, JY ;
Hervé, P ;
Tiberghien, P .
HUMAN GENE THERAPY, 1998, 9 (01) :73-80
[7]   Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia [J].
Dazzi, F ;
Szydlo, RM ;
Craddock, C ;
Cross, NCP ;
Kaeda, J ;
Chase, A ;
Olavarria, E ;
van Rhee, F ;
Kanfer, E ;
Apperley, JF ;
Goldman, JM .
BLOOD, 2000, 95 (01) :67-71
[8]   Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand [J].
Dazzi, F ;
Szydlo, RM ;
Goldman, JM .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (10) :1477-1486
[9]   Cytokine inhibitors and graft-versus-host disease [J].
Ferrara, JLM .
BONE MARROW TRANSPLANTATION: FOUNDATIONS FOR THE 21ST CENTURY, 1995, 770 :227-236
[10]  
FERRARA JLM, 1991, NEW ENGL J MED, V324, P667